Edition:
United Kingdom

Inovio Pharmaceuticals Inc (INO.OQ)

INO.OQ on NASDAQ Stock Exchange Global Select Market

4.43USD
9:00pm BST
Change (% chg)

$-0.06 (-1.34%)
Prev Close
$4.49
Open
$4.48
Day's High
$4.50
Day's Low
$4.36
Volume
151,481
Avg. Vol
215,198
52-wk High
$8.44
52-wk Low
$3.77

Chart for

About

Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery... (more)

Overall

Beta: 2.96
Market Cap(Mil.): $600.01
Shares Outstanding(Mil.): 90.23
Dividend: --
Yield (%): --

Financials

  INO.OQ Industry Sector
P/E (TTM): -- 84.11 32.75
EPS (TTM): -1.07 -- --
ROI: -53.08 1.56 14.38
ROE: -55.75 2.43 16.07

BRIEF-Inovio Pharmaceuticals Q1 Loss Per Share $0.36

* INOVIO PHARMACEUTICALS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS

09 May 2018

BRIEF-Inovio Pharmaceuticals Says For Qtr Ended March 31, Net Loss Per Share Was $0.36

* INOVIO PHARMACEUTICALS SAYS FOR THREE MONTHS ENDED MARCH 31, 2018, NET LOSS PER SHARE WAS $0.36 - SEC FILING

09 May 2018

BRIEF-Inovio Awarded Up To $56 Million From Cepi To Advance Dna Vaccines Against Lassa Fever And Mers

* INOVIO AWARDED UP TO $56 MILLION FROM CEPI TO ADVANCE DNA VACCINES AGAINST LASSA FEVER AND MERS

11 Apr 2018

BRIEF-Inovio Closes License And Collaboration Agreement With ApolloBio To Develop And Commercialize VGX-3100 In Greater China

* INOVIO CLOSES LICENSE AND COLLABORATION AGREEMENT WITH APOLLOBIO TO DEVELOP AND COMMERCIALIZE VGX-3100 IN GREATER CHINA

20 Mar 2018

BRIEF-Inovio Pharmaceuticals Reports Qtrly ‍Net Loss Attributable To Stockholders Of $0.24 Per Basic Share​

* INOVIO PHARMACEUTICALS REPORTS 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS

14 Mar 2018

BRIEF-Inovio's DNA Immunotherapy Demonstrates Immune Response Results Key In Treating Chronic Hepatitis B Infection

* INOVIO'S DNA IMMUNOTHERAPY DEMONSTRATES IMMUNE RESPONSE RESULTS KEY IN TREATING CHRONIC HEPATITIS B INFECTION Source text for Eikon: Further company coverage:

14 Mar 2018

BRIEF-Inovio Pharmaceuticals, Parker Institute For Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations

* INOVIO PHARMACEUTICALS AND THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY ESTABLISH CLINICAL DEVELOPMENT COLLABORATION TO EVALUATE NOVEL CANCER IMMUNOTHERAPY COMBINATIONS

09 Jan 2018

BRIEF-Inovio Receives Milestone Payment From Medimmune

* INOVIO RECEIVES MILESTONE PAYMENT FROM MEDIMMUNE AS MEDI0457 AND CHECKPOINT INHIBITOR COMBINATION TRIAL IN HEAD AND NECK SQUAMOUS CELL CANCER ADVANCES TO PHASE 2 Source text for Eikon: Further company coverage:

08 Jan 2018

BRIEF-Inovio Enters License, Collaboration Agreement With Apollobio To Develop, Commercialize VGX-3100 In Greater China

* INOVIO ENTERS LICENSE AND COLLABORATION AGREEMENT WITH APOLLOBIO TO DEVELOP AND COMMERCIALIZE VGX-3100 IN GREATER CHINA

02 Jan 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $121.32 -1.29
Novartis AG (NOVN.S) CHF75.60 +0.10
Pfizer Inc. (PFE.N) $36.16 -0.20
Merck & Co., Inc. (MRK.N) $60.99 -1.04
Sanofi SA (SASY.PA) €68.25 -0.43
GlaxoSmithKline plc (GSK.L) 1,552.80 -3.20
AstraZeneca plc (AZN.L) 5,383.00 -15.00

Earnings vs. Estimates